Overview

I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
- To evaluate Blood Pressure (BP) reduction to the targeted values (BP ≤ 140/90 mm Hg in non-diabetic patients, and ≤ 130/80 mm Hg in diabetic patients). - To emphasize and to evaluate the benefit of Irbesartan in the reduction of left ventricular mass index in hypertensive patients with left ventricular hypertrophy. - To demonstrate safety of Irbesartan in this population.
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Collaborator:
Bristol-Myers Squibb
Treatments:
Irbesartan